IBM Watson Establishes Hybrid Cloud Capabilities to Accelerate New Insights for The Enterprise
May 5 15
IBM announced that it is rolling out new hybrid cloud capabilities for IBM Watson that will help clients bridge enterprise data with web-based cloud applications for faster and more insightful data intelligence. This will bring together the powerful cognitive computing and content analytics capabilities from Watson with a growing list of Watson services found in the Watson Zone on Bluemix, IBM'scloud innovation platform that is based on open standards. A common challenge that arises with cognitive computing application development is where data resides. By integrating IBM Cloud capabilities for hybrid cloud, users now will be able to gain faster intelligence from data across multiple secure traditional and cloud environments, allowing clients to deploy applications in seconds and with minimal configuration. Watson Hybrid Cloud will use Watson Explorer a cognitive computing exploration capability for the enterprise as the on-premises platform for the application development, combining enterprise data sources into the application through a scalable environment that keeps utilized data local, private and a secure. Watson Explorer provides users with a complete view of contextually-relevant information to help them find and understand the information they need to work more efficiently, gain more insights from their unstructured content and improve business outcomes. Users will now be able to use the combined strength of analytics and cognitive capabilities in on-premises and public cloud capacity by tapping developer tools and services available on IBM Cloud, enabling them to start building their own hybrid Watson applications. The introduction of new connectors to the family of Watson services including the recent addition of the Alchemy API suite of services now part of the Watson ecosystem will give developers the ability to easily leverage services, applications and any of the 25 APIs already on the Watson Zone, built on public data into their development plans. This integrated development environment will facilitate access to advanced entity extraction, sentiment analysis, keyword extraction, tagging, and other capabilities to enrich the data in Watson Explorer. Using Alchemy API's concept tagging for instance, Watson Explorer can now employ sophisticated text analysis to tag documents in a manner similar to how people identify concepts in minutes versus days.
IBM Watson Health, Epic and Mayo Clinic to Unlock New Insights from Electronic Health Records
May 5 15
IBM Watson Health announced that it is collaborating with Epic and Mayo Clinic to advance patient health by applying the cognitive computing capabilities of Watson to Electronic Health Records (EHRs). As Watson's capabilities are applied to EHRs, patients and providers benefit from more rapid and thorough analysis of the medical factors that could impact an individual's health and wellness. Interoperability with Watson will enable these institutions to apply the cognitive capabilities of Watson to these records through secure, cloud-based Watson services, providing greater clinical insight to help personalize healthcare. Together, Watson and Epic software could be used to develop patient treatment protocols, personalize patient management for chronic conditions, and intelligently assist doctors and nurses by providing relevant evidence from the worldwide body of medical knowledge, putting new insight into the hands of clinical staff. Providers will be able to share patient-specific data with Watson in real time, within workflows, allowing Watson to bring forth critical evidence from medical literature and case studies that are most relevant to the patient's care. Epic plans to embed Watson's cognitive computing capabilities into its advanced decision support offerings through the use of open standards, including Health Level -7 (HL7) Fast Healthcare Interoperability Resources (FHIR) Application Programming Interfaces (APIs). Connecting through Epic's open API, the two systems will extend clinician expertise and help caregivers access knowledge more quickly. IBM and Mayo Clinic are already working together to pioneer cognitive computing in clinical trials matching for cancer patients. Watson's speed and accuracy allows physicians to enroll patients more quickly in the clinical trials that best meet individual patient needs. Over one million patients are seen at Mayo Clinic each year and more than 1,000 clinical trials are available to match patients to at any given time.
IBM Announces Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients
May 5 15
IBM Watson Health announced that it is collaborating with more than a dozen leading cancer institutes to accelerate the ability of clinicians to identify and personalize treatment options for their patients. The institutes will apply Watson's advanced cognitive capabilities to reduce from weeks to minutes the ability to translate DNA insights, understand a person's genetic profile and gather relevant information from medical literature to personalize treatment options. The project is part of IBM's broader Watson Health initiative to advance patient-centered care and improve health. The collaborations will enable clinicians to use Watson with a much broader set of patients by the end of 2015, and will accelerate the promise of personalized medicine for cancer patients everywhere. Ann & Robert H Lurie Children's Hospital of Chicago, BC Cancer Agency, City of Hope, Cleveland Clinic, Duke Cancer Institute, Fred & Pamela Buffett Cancer Center in Omaha, Nebraska, McDonnell Genome Institute at Washington University in St. Louis, New York Genome Center, Sanford Health, University of Kansas Cancer Center, University of North Carolina Lineberger Cancer Center, University of Southern California Center for Applied Molecular Medicine, University of Washington Medical Center, and Yale Cancer Center are among the first to participate in the project. As participating institutions use Watson to assist clinicians in identifying cancer-causing mutations, Watson's rationale and insights will continually improve, providing the latest combined wisdom of the cancer institutes for oncologists. In the initial phase of the program, participating organizations will apply Watson to the DNA data of patients who are battling all types of cancer, including lymphoma, melanoma, pancreatic, ovarian, brain, lung, breast and colorectal cancer. The new program builds on IBM Research advancements in analytics and existing Watson collaborations to develop a genome data analysis solution for clinicians. Partners involved in the program will use Watson Genomic Analytics, a new solution specifically designed for genomic analysis. Watson Genomic Analytics is a cloud-based service for evidence gathering and analysis. It looks for variations in the full human genome and uses Watson's cognitive capabilities to examine data sources such as treatment guidelines, research, clinical studies, journal articles and patient information. The solution then provides a list of medical literature that is relevant to the case along with drugs that have been identified in the literature. The patient's doctor then reviews this information alongside underlying evidence to make more informed treatment decisions. Watson Genomic Analytics constantly gets smarter, as the system learns from patient data.